Table 1 Patient characteristics according to EGFR-T790M mutation status
Characteristic | T790M + (n = 39) | T790M - (n = 39) | p value |
|---|---|---|---|
n (%) | n (%) | ||
Age | |||
Median (Range) | 73.0 (44.0–85.0) | 70.0 (55.0–88.0) | 0.224 |
Sex | |||
Male | 13 (33.3) | 15 (38.5) | 0.814 |
Female | 26 (66.7) | 24 (61.5) | |
PS | |||
0 | 26 (66.7) | 23 (59.0) | 0.682 |
1 | 11 (28.2) | 12 (30.8) | |
2 | 2 (5.1) | 4 (10.2) | |
Histology | |||
Adenocarcinoma | 38 (97.4) | 33 (84.6) | 0.025 |
Squamous cell carcinoma | 0 (0.0) | 6 (15.4) | |
NSCLC | 1 (2.6) | 0 (0.0) | |
Smoking status | |||
Never-smoker | 26 (66.6) | 23 (59.0) | 0.72 |
Ever-smoker | 6 (15.4) | 7 (17.9) | |
Current-smoker | 6 (15.4) | 9 (23.1) | |
NE | 1 (2.6) | 0 (0.0) | |
Stage | |||
III | 5 (12.8) | 3 (7.7) | 0.267 |
IV | 21 (53.8) | 28 (71.8) | |
Postoperative recurrence | 13 (33.4) | 8 (20.5) | |
EGFR mutation status | |||
Exon 19 deletion | 26 (66.7) | 20 (51.3) | 0.25 |
Exon 21 L858R | 13 (33.3) | 18 (46.1) | |
Other | 0 (0.0) | 1 (2.6) | |
EGFR-TKI | |||
Gefitinib | 23 (59.0) | 29 (74.4) | 0.369 |
Erlotinib | 9 (23.1) | 5 (12.8) | |
Afatinib | 7 (17.9) | 5 (12.8) | |
ORR | |||
CR/PR | 35 (89.7) | 20 (51.3) | < 0.001 |
SD | 4 (10.3) | 18 (46.1) | |
PD | 0 (0.0) | 1 (2.6) | |
Re-biopsy site | |||
within thorax | 11 (28.2) | 13 (33.3) | 0.77 |
out of thorax | 22 (56.4) | 22 (56.4) | |
plasma | 6 (15.4) | 4 (10.3) | |
MTS (%) | |||
Median (Range) | 42.7 (8.0–100.0) | 24.0 (−17–100.0) | 0.001 |
PFS duration | |||
< 6 months | 3 (7.7) | 10 (25.6) | 0.065 |
> =6 months | 36 (92.3) | 29 (74.4) | |